How AI Is Helping Cancer Patients: Saving Lives And...
Cancer treatment is costly. The average cost of cancer care in the U.S. is around $150,000 per patient—more than four times t [...]
Multimodal AI Test Predicts Prostate Cancer Metastasis and Treatment...
Leslie Ballas speaks with Timothy Showalter about a multimodal artificial intelligence-based prostate cancer test. Dr. Showal [...]
AI Model Identifies STAMPEDE Patients Needing Treatment Intensification –...
Zachary Klaassen interviews Nicholas James about applying the ArteraAI prostate test to high-risk M0 prostate cancer patients [...]
AI-Enabled Selection of Patients for Benefit of ADT +...
Dr. Nick James discusses intriguing data from STAMPEDE on the use of AI to analyze pathology slides and predict benefit from [...]
The ArteraAI Prostate Test Enhanced with New Insights for...
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated [...]
ASCO Oral Presentation
The STAMPEDE trials showed that adding abiraterone acetate + prednisolone (AAP) ± enzalutamide (ENZ) to standard of care andr [...]
External Validation of a Digital Pathology-Based Multimodal Artificial Intelligence-Derived...
Effective prognostication improves selection of patients with prostate cancer for treatment combinations. We aimed to evaluat [...]
Financial Assistance Application
The Artera Financial Assistance Program (“Program”) is designed for qualifying patients who are uninsured or are insured unde [...]